Other Vaccines - Switzerland

Switzerland

Highlights

The Other Vaccines market in Switzerland is anticipated to achieve a revenue of US$320.10m by the year 2024.
Furthermore, it is expected that the revenue will experience an annual growth rate (CAGR 2024-2029) of 10.29%, leading to a market volume of US$522.20m by the year 2029.
In a global context, United States is projected to generate the highest revenue of US$24.73bn in 2024.
Switzerland's rigorous regulatory framework and high healthcare standards make it a prime market for the development and distribution of innovative other vaccines.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Switzerland has been steadily growing in recent years, driven by a combination of factors including customer preferences, local special circumstances, and underlying macroeconomic factors.

Customer preferences: Swiss customers are increasingly concerned about their health and well-being, and as a result, demand for vaccines has been on the rise. In particular, there has been a growing interest in vaccines that protect against diseases such as meningitis, shingles, and HPV, which can have serious health consequences if left untreated. Additionally, Swiss customers are becoming more aware of the importance of vaccination in preventing the spread of infectious diseases, and are increasingly willing to invest in vaccines as a preventative measure.

Trends in the market: One of the key trends in the Other Vaccines market in Switzerland is the growing demand for travel vaccines. With Swiss tourists traveling to a wide range of destinations around the world, there is a growing need for vaccines that protect against diseases such as yellow fever, typhoid, and hepatitis A and B. Additionally, there has been a growing interest in vaccines that protect against emerging infectious diseases, such as Zika and Ebola.Another trend in the market is the increasing availability of new and innovative vaccines. As pharmaceutical companies continue to invest in research and development, new vaccines are being developed that offer improved efficacy and safety profiles compared to existing vaccines. For example, there are now vaccines available that protect against multiple strains of meningitis, as well as vaccines that offer improved protection against HPV.

Local special circumstances: Switzerland has a highly developed healthcare system, which has helped to drive demand for vaccines. The country has a strong tradition of preventative medicine, and as a result, there is a high level of awareness of the importance of vaccination. Additionally, the country has a highly educated population, which is able to make informed decisions about their healthcare.

Underlying macroeconomic factors: Switzerland is one of the wealthiest countries in the world, with a strong economy and high levels of disposable income. This has helped to drive demand for vaccines, as Swiss customers are able to afford the cost of vaccination. Additionally, the country has a highly developed pharmaceutical industry, which has helped to drive innovation in the Other Vaccines market. Finally, Switzerland has a highly educated workforce, which has helped to drive research and development in the pharmaceutical industry.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.